IRF5 and systemic lupus erythematosus: Somewhat surprisingly, we only detected a significant increase in the percentage of CD4+CD69+ T cells from IRF5-SLE homozygous risk carriers and not from SLE patients (Figure 1G, Supplementary Figure S1C).